Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA.
The Kiryas Joel community in Monroe, N.Y. was the site of the first clinical trial which proved the protective efficacy of hepatitis A vaccine. The vaccine used was VAQTA J. Med. Virol (hepatitis A vaccine, inactivated). In the 9 years since the trial ended vaccination of infants reaching 2 years of age has continued along with monitoring for hepatitis A cases. The prevaccine pattern of frequent outbreaks has converted to a sustained pattern of no outbreaks, despite sporadic introduction of hepatitis A into the community in nonvaccinees. Community use of VAQTA in children 2 years of age and older has proven capable of providing long-term prevention of hepatitis A outbreaks in a formerly frequently affected community despite prolonged sporadic introduction of the virus.
Werzberger
Alan
A
Mensch
Barbara
B
Nalin
David R
DR
Kuter
Barbara J
BJ
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks; D005500:Follow-Up Studies; D006506:Hepatitis A / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines / Q000008:administration & dosage*; D006508:Hepatitis Antibodies / Q000097:blood; D006801:Humans; D009518:New York / Q000453:epidemiology
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies